Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
-
Patent number: 11786591Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
-
Patent number: 11787764Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.Type: GrantFiled: February 14, 2019Date of Patent: October 17, 2023Assignees: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Martin John Schnermann, Peter C. W. Kim, Jaepyeong Cha, Roger Rauhauser Nani
-
Publication number: 20230321240Abstract: Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R273C or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: September 2, 2021Publication date: October 12, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Sanghyun Kim, Nikolaos Zacharakis, Steven A. Rosenberg
-
Patent number: 11782065Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.Type: GrantFiled: December 21, 2021Date of Patent: October 10, 2023Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
-
Patent number: 11780931Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.Type: GrantFiled: December 14, 2021Date of Patent: October 10, 2023Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of CaliforniaInventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
-
Patent number: 11779570Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: October 10, 2023Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Patent number: 11781955Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: GrantFiled: September 21, 2020Date of Patent: October 10, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Patent number: 11779601Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.Type: GrantFiled: May 27, 2016Date of Patent: October 10, 2023Assignees: Kite Pharma, Inc., The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Patent number: 11779603Abstract: Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an ? chain (such as SEQ ID NO: 2) and a ? chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR ? and/or ? chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR ? chain and the TCR ? chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR ? chain and the TCR ? chain, and administering a composition comprising the modified T cells to the subject.Type: GrantFiled: June 30, 2017Date of Patent: October 10, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Richard W. Childs, Michael I. Nishimura, Elena A. Cherkasova
-
Patent number: 11780885Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: GrantFiled: November 15, 2017Date of Patent: October 10, 2023Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Kimberly Dowd, Barney S. Graham, Sung-Youl Ko, Wing-Pui Kong, John Mascola, Theodore Pierson, Mayuri Sharma, Dong Yu
-
Publication number: 20230312672Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD20 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: June 23, 2021Publication date: October 5, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kazusa Ishii, Christian S. Hinrichs
-
Patent number: 11773412Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.Type: GrantFiled: June 24, 2022Date of Patent: October 3, 2023Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Rutgers, the State University of New Jersey, Skolkovo Institute of Science and Technology, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Konstantin Severinov, Feng Zhang, Yuri I. Wolf, Sergey Shmakov, Ekaterina Semenova, Leonid Minakhin, Kira S. Makarova, Eugene Koonin, Silvana Konermann, Julia Joung, Jonathan S. Gootenberg, Omar O. Abudayyeh, Eric S. Lander
-
Patent number: 11771737Abstract: In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of vancomycin and a checkpoint inhibitor. In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of a primary bile acid.Type: GrantFiled: October 29, 2018Date of Patent: October 3, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Tim F. Greten, Chi Ma
-
Publication number: 20230303976Abstract: Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.Type: ApplicationFiled: February 27, 2023Publication date: September 28, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Alena Gros, Steven A. Rosenberg
-
Patent number: 11767498Abstract: An in vitro tissue plate may include a well plate, a fluidic plate disposed on a bottom surface of the well plate, and a media manifold disposed on a bottom surface of the fluidic plate. The well plate may have at least two wells, including a tissue well and a waste well. The fluid plate may include a fluid channel extending between and fluidly connecting the tissue well to the waste well. The media manifold may include a one or more media outlets fluidly connected to the fluid channel. A tissue layer may be deposited in the tissue well. The tissue layer may include human cells such as neurovascular cells.Type: GrantFiled: June 26, 2020Date of Patent: September 26, 2023Assignees: Massachusetts Institute of Technology, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Johanna Bobrow, Todd Thorsen, David Walsh, Christina Zook, Min Jae Song, Marc Ferrer-Alegre, Sam Michael, Yen-Ting Tung, Molly Elizabeth Boutin
-
Publication number: 20230295550Abstract: Provided are inserts (100) for preparing a cell culture chamber(s), or array of chambers, inside of histology cassettes that are suitable for three-dimensional multicellular growth of a cell or cells into spheroids, organoids, or other 3D structures, such that the resulting 3D multi-cellular structures are ready and suitable for histology processing without transfer to a different receptacle or container. Further embodiments of the invention provide methods of preparing at least one cell culture chamber using the inserts, systems for growing three-dimensional multicellular spheroids comprising culturing cells within a cell culture chamber prepared using the inserts, and systems for analyzing at least one cultured cell in vitro comprising culturing cells within a cell culture chamber prepared using the inserts.Type: ApplicationFiled: July 30, 2021Publication date: September 21, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Ralph E. Parchment, Thu A. Nguyen
-
Patent number: 11760794Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: GrantFiled: April 28, 2021Date of Patent: September 19, 2023Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Patent number: 11760790Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: February 21, 2019Date of Patent: September 19, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Paolo Lusso, Qingbo Liu, Peter Kwong, John Mascola, Young Do Kwon
-
Patent number: 11759513Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: GrantFiled: October 29, 2021Date of Patent: September 19, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Yuhuan Wang
-
Publication number: 20230287067Abstract: The invention provides human immunogenic epitopes of HEMO and HHLA2 human endogenous retroviruses (HERVs), which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.Type: ApplicationFiled: January 21, 2021Publication date: September 14, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Jeffrey Schlom, Duane H. Hamilton, Claudia M. Palena, Renee N. Donahue